Bradford S. Goodwin

Bradford S. Goodwin, the Chief Executive Officer is an experienced biotech executive. Mr. Goodwin also serves as a director of Rigel, Inc., a public biotechnology company focused on small molecule drug development. Previously he was Chairman of the Board of Facet Biotech Corp., a monoclonal antibody research and development company, which was sold to Abbott Laboratories for $722 million in April 2010, Chairman of the Board of PDL BioPharma, a monoclonal antibody company earning $300 million per year in royalties, Chairman of the Board of CoTherix, Inc. a company commercializing Ventavis for pulmonary arterial hypertension that was sold to Actelion in 2007 for $420 million, and a director of NeurogesX. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea, Inc., an oncology drug development company that he built from a start up with one employee and one preclinical compound into a public company with three clinical stage products. At Novacea, he led four rounds of financings that raised over $140 million, including its IPO in 2006, and licensed two clinical stage compounds. He led the efforts to obtain a major corporate partnership for the company's lead product, which was consummated shortly after he departed. Prior to Novacea, Mr. Goodwin was Vice President of Finance at Genentech, Inc. where he assisted in the commercialization of the first two FDA approved monoclonal antibodies for cancer: Rituxan® and Herceptin®.